Billions is launching a Discord real-world verification solution, with Human Pass set to officially go live soon
BlockBeats News, June 5th, according to official sources, Billions announced that its identity verification product, Human Pass, built on Proof of Uniqueness technology, is set to land on Discord. This will provide online communities with a trustworthy and privacy-friendly real-world verification infrastructure.
With the rapid growth of AI and automated accounts, community size has become inadequate to reflect genuine user engagement. Human Pass aims to assist Discord communities in identifying real and unique human members, establishing a higher-quality interactive environment under privacy protection. It will provide a trustworthy human identity layer for use cases such as reward distribution, community governance, member access, and exclusive benefits.
Upon completing the verification, users will receive a Human Pass identity badge to prove their status as a real and unique human individual, not a bot or mass-created account. This solution employs privacy-enhancing technologies like zero-knowledge proofs, does not store personal data, and does not retain facial images, achieving a balance between identity verification and privacy protection.
Billions stated that Human Pass will first open to the Discord community, further driving the internet's evolution from an "account network" to a "Human Network," establishing a trustworthy human participation infrastructure for the next generation of digital communities.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
